Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D12DYT
|
|||
| Drug Name |
HPN217
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1 | [1] | |
| Company |
AbbVie
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04184050) A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AbbVie. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.